Table 1 Characteristics of the included studies, 2011–18
Author (s), Year | Country | #Partici-pants | Age group, median | Study population characteristics | Histology profiles |
|---|---|---|---|---|---|
Ratnam, 2011 | Canada | 1418 | 15–80, 30.6 | Women referred to colposcopy and those routinely screened | Normal = 651, CIN1 = 366, CIN2 = 120, CIN2 + =401, CIN3 = 281 |
Waldstrom, 2011 | Denmark | 405 | 16–65, 32 | Three years archived liquid-based samples, all with a diagnosis of LSIL | CIN2 + =67, CIN3 + =33 |
Fan, 2018 | China | 192 | No data | Patients with abnormal cytology results and/or high-risk HPV infection | CIN1- = 41, CIN1 = 54, CIN2 = 28, CIn3 = 53, cancer = 16 |
Han,2018 | China | 197 | No data | Women with abnormal cytological or HPV test results | CIN1- = 80, CIN1 = 16, CIN2/3 = 50, Caner = 51 |
Binnicker,2014 | USA | 350 | No data | Residual specimens with a cytologic result of ≥ atypical squamous cells of undetermined significance (ASC-US) | CIN2 + =81, CIN3 + =41 |
Broccolo,2013 | Italy | 308 | 20–65 | A retrospective study on cervical cytology specimens | Normal = 70, CIN1 = 159, CIN2 + =79 |
Waldstrom, 2012 | Denmark | 235 | 30–69, 42.2 | Women with ASC-US cytology | Normal = 86, CIN1 = 35, CIN2 = 21, CIN3 = 26, Cancer = 1 |
Li,2017 | China | 318 | No data | Women with ASCUS cytology attending routine outpatient primary cervical screening | Normal = 169, CIN1 = 74, CIn2 = 40, CIN3 = 16, cancer = 19 |
Benevolo,2011 | Italy | 464 | 17–78, 32 | Hybrid Capture 2 (HC2)-positive patients, who underwent colposcopy | <CIN2 = 49, CIN2 + =49, SCC = 9 |
Wang, 2019 | Korea | 563 | 20–84, no | Liquid-based cytology samples | Normal = 51, CIN1 = 75, CIN2 = 16, CIN3 = 40, cancer = 38 |
Liu, 2014 | China | 335 | No data | Women who underwent outpatient hospital-based gynecological screening | Normal = 30, CIN1 = 5, CIN2 = 1,CIn3 = 15, Cancer 41 |
Iftner, 2015 | Germany | 9451 | 30–60 | Women undergoing routine cervical screening | <CIN2 = 513, CIN2 = 47, CIN3 + =43 |
Sorbye, 2011 | Norway | 520 | 25–69 | Post-colposcopy follow-up of women with negative or low-grade biopsy | CIN2- = 396, CIN2 + = 124 |
Duvlis, 2015 | Macedonian | 413 | 19–78 | Women that come for cervical cancer screening | Normal = 10, CIN1 = 22, CIN2 = 20, CIN3 = 9 |
Castro, 2013 | Spain | 165 | 18–75, 34.8 | Women with endocervical samples harboring HPV 16 and/or 18 DNA | CIN2- = 93, CIN2 + = 72 |
Pierry, 2012 | USA | 246 | 19–75 | Women in a higher risk urban screening population | Normal = 137, CIN1 = 64, CIN2 = 25, CIN3 = 20 |
Alaghehbandan, 2013 | Canada | 1360 | 15–80, 30.7 | women with a history of abnormal cytology referred to colposcopy | Normal = 635, CIN1 = 345, CIN2 + =380, Cancer = 10 |
Clad, 2011 | Germany | 424 | No data | Women referred to colposcopy due to an abnormal Pap smear | Normal = 108, CIN1 = 64, CIN2 = 89, CIN3 = 150, Cancer = 13 |
Varnai, 2018 | Germany | 66 | 21–66, 34.6 | Office based screening population who were HPV-DNA positive for at least one of the following HR- HPV types: HPV 16, 18, 31, 33 and 45 | Normal = 6, CIN2 = 5, CIN3 = 22 |
Coquillard, 2011 | USA | 2049 | No data | Women both low and high risk | Normal = 1694, CIN1 = 78 CIN2 + =73 |
Shen, 2013 | China | 272 | 16–77, 37 | Women with abnormal colposcopy | CIN1- = 80, CIN2 = 6, CIN3 + =25 |
Li, 2016 | China | 186 | 22–68 | Patients underwent colposcopy | Normal = 32, CIN1 = 51, CIN2/3 = 71, cancer = 32 |
Liu, 2017 | China | 380 | > 30 | Women who were associated with high risk of cervical virus infection | Normal = 159, CIN1 = 68, CIN2 = 74, CIN3 = 68, cancer = 11 |
Benevolo, 2011 | Italy | 1610 | 18–83, 39.5 | Retrospective analysis of women underwent an E6/E7 mRNA test on cervical samples | Normal = 74, CIN1 = 282, CIN2 = 120, CIN3 = 86, cancer = 24 |
Liu, 2018 | Japan | 171 | 22–76, 33 | Women with pathologically-diagnosed CIN or cervical carcinoma | CIN1 = 16, CIN2 = 33, CIN3 = 83, SCC = 39 |
Persson, 2014 | Sweden | 219 | 23–60, 32 | HR-HPV-positive women diagnosed with atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) | Normal = 56, CIN1 = 69, CIn2 = 37, CIN3+ 36 |
Sorbye, 2011 | Norway | 297 | 25–69 | Women with ASC-US and LS | CIN1- = 53, CIN2 + =69 |
Andersson, 2011 | Sweden | 204 | 21–79, 32 | Women who were undergoing gynecological screening or had been admitted to a referral center | Normal = 45, CIN1 = 33, CIn2 = 28, CIN3 = 31, Cancer 28 |
Oliveira, 2013 | Portugal | 554 | 18–73, 33 | Women were referred for opportunistic screening and for evaluation of HPV associated lesions | Normal = 131, CIN1 = 128, CIn2 = 129, CIN3 = 146, Cancer = 14 |